Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.

NCT03634345

Last updated date
Study Location
Pfizer Clinical Research Unit
Brussels, , B-1070, Belgium
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Dermatitis, Atopic
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male or female subjects.

- Body mass index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight >50 kg (110 lb).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal,
cardiovascular, hepatic, psychiatric, neurological, or allergic disease.


- Evidence or history of clinically significant dermatological condition (eg, contact
dermatitis or psoriasis) or visible rash present during physical examination.


- History of hypersensitivity to or intolerance of fluvoxamine and/or fluconazole.


- Any condition possibly affecting drug absorption.


- A positive urine drug test.


- Screening supine systolic BP <90 mm Hg or 140 mm Hg following at least 5 minutes of
supine rest OR Screening supine diastolic BP <50 mm Hg or 90 mm Hg following at least
5 minutes of supine rest.


- Pregnant female subjects; breastfeeding female subjects; fertile male subjects and
female subjects of childbearing potential who are unwilling or unable to use a highly
effective method of contraception.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Dermatitis, AtopicDrug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842. NCT03634345
  1. Brussels,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Dermatitis, AtopicCrisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis NCT03233529
  1. Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Dermatitis, AtopicStudy Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis NCT03575871
  1. New York, New York
  2. Carlton, Victoria
  3. Nachod,
  4. Blankenfelde-Mahlow,
  5. Anaheim, California
  6. Rolling Hills Estates, California
  7. Santa Monica, California
  8. Colorado Springs, Colorado
  9. Colorado Springs, Colorado
  10. Jacksonville, Florida
  11. Jacksonville, Florida
  12. Jacksonville, Florida
  13. Orlando, Florida
  14. Tampa, Florida
  15. Caldwell, Idaho
  16. Nampa, Idaho
  17. Baton Rouge, Louisiana
  18. Boston, Massachusetts
  19. Saint Joseph, Missouri
  20. Wilmington, North Carolina
  21. Columbus, Ohio
  22. Gahanna, Ohio
  23. Memphis, Tennessee
  24. Memphis, Tennessee
  25. Austin, Texas
  26. Houston, Texas
  27. Franklin, Virginia
  28. Norfolk, Virginia
  29. Maroubra, New South Wales
  30. Benowa, Queensland
  31. Woolloongabba, Queensland
  32. East Melbourne, Victoria
  33. Parkville, Victoria
  34. Parkville, Victoria
  35. Dupnitsa,
  36. Gabrovo,
  37. Sofia,
  38. Sofia,
  39. Sofia,
  40. Sofia,
  41. Vancouver, British Columbia
  42. Winnipeg, Manitoba
  43. North York, Ontario
  44. Oshawa, Ontario
  45. Richmond Hill, Ontario
  46. Toronto, Ontario
  47. Sherbrooke, Quebec
  48. Beijing, Beijing
  49. Chongqing, Chongqing
  50. Shenzhen, Guangdong
  51. Beijing,
  52. Tianjin,
  53. Nachod,
  54. Nachod,
  55. Praha 1,
  56. Praha 2,
  57. Svitavy,
  58. Svitavy,
  59. Bad Bentheim,
  60. Berlin,
  61. Frankfurt,
  62. Hamburg,
  63. Münster,
  64. Schwerin,
  65. Budapest,
  66. Budapest,
  67. Debrecen,
  68. Kecskemet,
  69. Szolnok,
  70. Yokohama, Kanagawa
  71. Kamimashiki-gun, Kumamoto
  72. Neyagawa, Osaka
  73. Sakai, Osaka
  74. Edogawa-ku, Tokyo
  75. Nakano-ku, Tokyo
  76. Fukuoka,
  77. Saitama,
  78. Bucheon-si, Gyeonggi-do
  79. Bupyeong-gu, Incheon
  80. Jung-gu, Incheon
  81. Daegu,
  82. Gwangju,
  83. Seoul,
  84. Seoul,
  85. Seoul,
  86. Seoul,
  87. Seoul,
  88. Jelgava,
  89. Riga,
  90. Riga,
  91. Riga,
  92. Riga,
  93. Bialystok,
  94. Białystok,
  95. Krakow,
  96. Kraków,
  97. Kraków,
  98. Lodz,
  99. Lublin,
  100. Szczecin,
  101. Warszawa,
  102. Warszawa,
  103. Warszawa,
  104. Warszawa,
  105. Wroclaw,
  106. Wrocław,
  107. Plymouth, Devon
  108. Blackpool, Lancashire
  109. Cannock, South Staffordshire
  110. Barnsley, South Yorkshire
  111. Bristol,
  112. Manchester,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Dermatitis, AtopicStudy to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis NCT03349060
  1. Calgary, Alberta
  2. Calgary, Alberta
  3. Calgary, Alberta
  4. Surrey, British Columbia
  5. Surrey, British Columbia
  6. Vancouver, British Columbia
  7. Winnipeg, Manitoba
  8. Markham, Ontario
  9. Peterborough, Ontario
  10. Richmond Hill, Ontario
  11. Richmond Hill, Ontario
  12. Toronto, Ontario
  13. Montreal, Quebec
  14. Sherbrooke, Quebec
  15. Kutna Hora,
  16. Kutna Hora,
  17. Ostrava - Poruba,
  18. Ostrava - Poruba,
  19. Praha 1,
  20. Praha 2,
  21. Usti nad Labem,
  22. Usti nad Labem,
  23. Luebeck, Schleswig-holstein
  24. Münster,
  25. Kecskemet, Bács-kiskun
  26. Debrecen,
  27. Miskolc,
  28. Pecs,
  29. Katowice,
  30. Katowice,
  31. Katowice,
  32. Katowice,
  33. Lodz,
  34. Lodz,
  35. Ostrowiec Swietokrzyski,
  36. Warszawa,
  37. Birmingham, Alabama
  38. Encinitas, California
  39. San Diego, California
  40. San Diego, California
  41. Santa Monica, California
  42. Coral Gables, Florida
  43. Largo, Florida
  44. Tampa, Florida
  45. Savannah, Georgia
  46. Skokie, Illinois
  47. Indianapolis, Indiana
  48. Indianapolis, Indiana
  49. Boston, Massachusetts
  50. Detroit, Michigan
  51. Troy, Michigan
  52. Saint Joseph, Missouri
  53. Oklahoma City, Oklahoma
  54. Tulsa, Oklahoma
  55. Portland, Oregon
  56. Charleston, South Carolina
  57. Charleston, South Carolina
  58. Arlington, Texas
  59. Houston, Texas
  60. San Antonio, Texas
  61. Norfolk, Virginia
  62. Lakewood, Washington
  63. Tacoma, Washington
  64. Tacoma, Washington
  65. Tacoma, Washington
  66. Maroubra, New South Wales
  67. Maroubra, New South Wales
  68. Upper Mount Gravatt, Queensland
  69. Woolloongabba, Queensland
  70. Camberwell, Victoria
  71. Carlton, Victoria
  72. Carlton, Victoria
  73. East Melbourne, Victoria
  74. Parkville, Victoria
  75. Richmond, Victoria
  76. Bad Bentheim,
  77. Berlin,
  78. Berlin,
  79. Dresden,
  80. Erlangen,
  81. Kiel,
  82. Munich,
  83. Schwerin,
  84. Plymouth, Devon
  85. London, Greater London
  86. Sheffield, South Yorkshire, England
  87. Sheffield, South Yorkshire
  88. Dudley,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
Official Title  ICMJE A PHASE 1, OPEN-LABEL, RANDOMIZED, FIXED-SEQUENCE, PARALLEL-COHORT STUDY TO ESTIMATE THE EFFECT OF FLUVOXAMINE OR FLUCONAZOLE, ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A SINGLE DOSE OF PF-04965842 IN HEALTHY SUBJECTS
Brief Summary A Phase 1, Open Label, Parallel-Cohort, Randomized, Fixed Sequence Study To Evaluate The Pharmacokinetic Drug Drug Interaction Between PF-04965842 and Fkuvoxamine (cohort 1) or Fluconazole (Cohort 2) in healthy subjects.
Detailed Description

A phase 1 study to evaluate the effect of fluvoxamine (a strong CYP2C19 and moderate CYP3A inhibitor) or fluconazole (a strong CYP2C19, moderate CYP2C9 and CYP3A inhibitor) on the pharmacokinetics, safety and tolerability of PF-04965842 in healthy subjects.

This study will be a Phase 1, open label, randomized, fixed-sequence, parallel-cohort study drug-drug interaction study. The study includes 2 periods:

In Period 1: all subjects will receive one single oral dose of 100 mg PF 04965842 tablet. (Treatment A). PK will be evaluated in the first 72 hours post adminstration of PF 04965842.

In Period 2:

  • Cohort 1: subjects will receive fluvoxamine (immediate release tablet 50 mg) once daily for 9 consecutive days; on Day 8, subjects will receive a single oral dose of 100 mg PF 04965842 approximately 3 hours after fluvoxamine administration. (Treatment B). PK will be evaluated in the first 72 hours post administration of PF 04965842.
  • Cohort 2: subjects will receive fluconazole capsule(s) once daily for 7 consecutive days (400 mg on Day 1 and 200 mg on Day 2-7 in Period 2); on Day 5, subjects will receive a single oral dose of 100 mg PF 04965842 approximately 1 hour after fluconazole administration. (Treatment C). PK will be evaluated in the first 72 hours post administration of PF 04965842.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Dermatitis, Atopic
Intervention  ICMJE
  • Drug: Period 1 - Day 1: PF-04965842 administered
    Period 1: Single administration of 100 mg PF 04965842.
    Other Name: Single administration of PF-04965842 in Period 1.
  • Drug: Period 2: Cohort 1: Fluvoxamine & PF-04965842
    Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
    Other Name: 9-day administration of Fluvoxamine and single administration of PF-04965842 on day 8.
  • Drug: Period 2: Cohort 2: Fluconazole & PF-04965842
    Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
    Other Name: 7-day administration of fluconazole and single administration of PF-04965842 on day 5.
Study Arms  ICMJE Experimental: PF-04965842
investigational drug
Interventions:
  • Drug: Period 1 - Day 1: PF-04965842 administered
  • Drug: Period 2: Cohort 1: Fluvoxamine & PF-04965842
  • Drug: Period 2: Cohort 2: Fluconazole & PF-04965842
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 14, 2018)
24
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 13, 2018
Actual Primary Completion Date December 13, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy male or female subjects.
  • Body mass index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight >50 kg (110 lb).

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
  • Evidence or history of clinically significant dermatological condition (eg, contact dermatitis or psoriasis) or visible rash present during physical examination.
  • History of hypersensitivity to or intolerance of fluvoxamine and/or fluconazole.
  • Any condition possibly affecting drug absorption.
  • A positive urine drug test.
  • Screening supine systolic BP <90 mm Hg or 140 mm Hg following at least 5 minutes of supine rest OR Screening supine diastolic BP <50 mm Hg or 90 mm Hg following at least 5 minutes of supine rest.
  • Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03634345
Other Study ID Numbers  ICMJE B7451017
2018-001943-29 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP